The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jan 19, 2023

Keywords

ClinConnect Summary

The UPDATE Trial is studying the effectiveness of a treatment called NB-UVB phototherapy for adults with atopic dermatitis, also known as eczema. This trial aims to find out if this light therapy, combined with optimal topical treatments (like creams and ointments), is better at managing eczema compared to using topical treatments alone. Participants will be divided into two groups: one will receive the light therapy for 8-16 weeks along with topical treatments, while the other group will only use the topical treatments for at least three months.

To participate in the trial, individuals must be at least 18 years old and have eczema that is not well controlled by standard treatments. They should have moderate eczema based on specific assessment tools. However, certain individuals may not qualify, such as those with specific skin conditions or those who have recently undergone other treatments. Participants in the trial can expect regular check-ins and assessments throughout the study to monitor their skin condition and overall health. This trial is currently recruiting, and it's a great opportunity for those looking for new ways to manage their eczema.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (≥18 years of age) patient meeting the UK working party criteria for atopic eczema;
• • AE insufficiently controlled by standard topical care and therefore eligible for NB-UVB or OTT;
• • Investigator Global Assessment (IGA, 0-4) of ≥ 2 (moderate disease);
• • Eczema Area and Severity Index (EASI) of ≥ 7 (moderate disease);
• • Understood and voluntarily signed and dated an informed consent form prior to any study-related procedure or has a legal representative who has, and is willing to comply with the study's requirements.
• Exclusion Criteria:
• • Contra-indication for NB-UVB;
• • Genetic defects associated with photosensitivity or skin cancer;
• • Heavily photo-damaged skin;
• • History of multiple (\>1) skin malignancies;
• • Use of systemic immunosuppressants/immunomodulators;
• • Use of medication associated with photosensitivity;
• • Patient is already on systemic AE therapy;
• • Patient is already on OTT in the past 2 months;
• • NB-UVB or any systemic therapy in the past 9 months.